Signs and symptoms of overdosage may include, alone or in combination, any of the following: drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions, and coma; rapid and irregular pulse, hypertension, hypotension and vascular collapse; precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin.
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Levodopa | The risk or severity of hypotension and orthostatic hypotension can be increased when Rasagiline is combined with Levodopa. |
| Risperidone | Rasagiline may increase the hypotensive activities of Risperidone. |
| Deferasirox | The serum concentration of Rasagiline can be increased when it is combined with Deferasirox. |
| Peginterferon alfa-2b | The serum concentration of Rasagiline can be increased when it is combined with Peginterferon alfa-2b. |
| Leflunomide | The serum concentration of Rasagiline can be decreased when it is combined with Leflunomide. |
| Teriflunomide | The serum concentration of Rasagiline can be decreased when it is combined with Teriflunomide. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Rasagiline. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Rasagiline. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Rasagiline. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Rasagiline. |
| Magnesium sulfate | The therapeutic efficacy of Rasagiline can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Rasagiline may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Rasagiline. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Rasagiline. |
| Orphenadrine | Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Rasagiline. |
| Pramipexole | Rasagiline may increase the sedative activities of Pramipexole. |
| Ropinirole | Rasagiline may increase the sedative activities of Ropinirole. |
| Rotigotine | Rasagiline may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Rasagiline. |
| Sodium oxybate | Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Thalidomide | Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methylergometrine | The risk or severity of hypertension can be increased when Methylergometrine is combined with Rasagiline. |
| Nicergoline | The risk or severity of hypertension can be increased when Nicergoline is combined with Rasagiline. |
| Phenmetrazine | The risk or severity of hypertension can be increased when Phenmetrazine is combined with Rasagiline. |
| Dutasteride | The risk or severity of hypertension can be increased when Dutasteride is combined with Rasagiline. |
| Finasteride | The risk or severity of hypertension can be increased when Finasteride is combined with Rasagiline. |
| Ephedrine | The risk or severity of hypertension can be increased when Ephedrine is combined with Rasagiline. |
| Epicaptopril | The risk or severity of hypertension can be increased when Rasagiline is combined with Epicaptopril. |
| Taxifolin | The risk or severity of hypertension can be increased when Rasagiline is combined with Taxifolin. |
| 1-benzylimidazole | The risk or severity of hypertension can be increased when Rasagiline is combined with 1-benzylimidazole. |
| Dronedarone | The risk or severity of hypertension can be increased when Rasagiline is combined with Dronedarone. |
| Amibegron | The risk or severity of hypertension can be increased when Rasagiline is combined with Amibegron. |
| Nylidrin | The risk or severity of hypertension can be increased when Rasagiline is combined with Nylidrin. |
| Solabegron | The risk or severity of hypertension can be increased when Rasagiline is combined with Solabegron. |
| Saralasin | The risk or severity of hypertension can be increased when Rasagiline is combined with Saralasin. |
| Tyramine | The risk or severity of hypertension can be increased when Rasagiline is combined with Tyramine. |
| Adrafinil | The risk or severity of hypertension can be increased when Rasagiline is combined with Adrafinil. |
| Etilefrine | The risk or severity of hypertension can be increased when Rasagiline is combined with Etilefrine. |
| Synephrine | The risk or severity of hypertension can be increased when Rasagiline is combined with Synephrine. |
| Dihydroergocornine | The risk or severity of hypertension can be increased when Rasagiline is combined with Dihydroergocornine. |
| Amitraz | The risk or severity of hypertension can be increased when Rasagiline is combined with Amitraz. |
| Atipamezole | The risk or severity of hypertension can be increased when Rasagiline is combined with Atipamezole. |
| Ractopamine | The risk or severity of hypertension can be increased when Rasagiline is combined with Ractopamine. |
| Anisodamine | The risk or severity of hypertension can be increased when Rasagiline is combined with Anisodamine. |
| Tulobuterol | The risk or severity of hypertension can be increased when Rasagiline is combined with Tulobuterol. |
| Dopexamine | The risk or severity of hypertension can be increased when Rasagiline is combined with Dopexamine. |
| Siponimod | The risk or severity of hypertension can be increased when Rasagiline is combined with Siponimod. |
| Idazoxan | The risk or severity of hypertension can be increased when Rasagiline is combined with Idazoxan. |
| Ebselen | The risk or severity of hypertension can be increased when Rasagiline is combined with Ebselen. |
| Higenamine | The risk or severity of hypertension can be increased when Rasagiline is combined with Higenamine. |
| Reproterol | The risk or severity of hypertension can be increased when Rasagiline is combined with Reproterol. |
| Tramazoline | The risk or severity of hypertension can be increased when Rasagiline is combined with Tramazoline. |
| Octopamine | The risk or severity of hypertension can be increased when Rasagiline is combined with Octopamine. |
| Fenozolone | The risk or severity of hypertension can be increased when Rasagiline is combined with Fenozolone. |
| Dihydroergocristine | The risk or severity of hypertension can be increased when Rasagiline is combined with Dihydroergocristine. |
| Norfenefrine | The risk or severity of hypertension can be increased when Rasagiline is combined with Norfenefrine. |
| Dihydroergocryptine | The risk or severity of hypertension can be increased when Rasagiline is combined with Dihydroergocryptine. |
| Oxyfedrine | The risk or severity of hypertension can be increased when Rasagiline is combined with Oxyfedrine. |
| Terguride | The risk or severity of hypertension can be increased when Rasagiline is combined with Terguride. |
| Xenon | The risk or severity of adverse effects can be increased when Xenon is combined with Rasagiline. |
| Rimiterol | The risk or severity of hypertension can be increased when Rasagiline is combined with Rimiterol. |
| Tretoquinol | The risk or severity of hypertension can be increased when Rasagiline is combined with Tretoquinol. |
| Prenalterol | The risk or severity of hypertension can be increased when Rasagiline is combined with Prenalterol. |
| Xamoterol | The risk or severity of hypertension can be increased when Rasagiline is combined with Xamoterol. |
| Mefenorex | The risk or severity of hypertension can be increased when Rasagiline is combined with Mefenorex. |
| Deoxyepinephrine | The risk or severity of hypertension can be increased when Rasagiline is combined with Deoxyepinephrine. |
| Quinoline Yellow WS | The risk or severity of hypertension can be increased when Rasagiline is combined with Quinoline Yellow WS. |
| Selpercatinib | The risk or severity of hypertension can be increased when Rasagiline is combined with Selpercatinib. |
| Naxitamab | The risk or severity of hypertension can be increased when Rasagiline is combined with Naxitamab. |
| Apraclonidine | Rasagiline may increase the alpha-adrenergic activities of Apraclonidine. |
| Atomoxetine | The risk or severity of adverse effects can be increased when Rasagiline is combined with Atomoxetine. |
| Betahistine | The metabolism of Betahistine can be decreased when combined with Rasagiline. |
| Bezafibrate | Rasagiline may increase the hepatotoxic activities of Bezafibrate. |
| Buprenorphine | Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Bupropion | The risk or severity of adverse effects can be increased when Rasagiline is combined with Bupropion. |
| Buspirone | The risk or severity of hypertension can be increased when Rasagiline is combined with Buspirone. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Rasagiline. |
| Cyclobenzaprine | Cyclobenzaprine may increase the serotonergic activities of Rasagiline. |
| Cyproheptadine | Rasagiline may increase the anticholinergic activities of Cyproheptadine. |
| Dextromethorphan | The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Dextromethorphan. |
| Diethylpropion | The risk or severity of adverse effects can be increased when Rasagiline is combined with Diethylpropion. |
| Domperidone | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Rasagiline is combined with Domperidone. |
| Hydrocodone | Rasagiline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydromorphone | Rasagiline may increase the serotonergic activities of Hydromorphone. |
| Isometheptene | Rasagiline may increase the sympathomimetic activities of Isometheptene. |
| Levonordefrin | Rasagiline may increase the hypertensive activities of Levonordefrin. |
| Lithium hydroxide | The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Lithium hydroxide. |
| Lithium citrate | The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Lithium citrate. |
| Maprotiline | The risk or severity of adverse effects can be increased when Rasagiline is combined with Maprotiline. |
| Mianserin | The risk or severity of adverse effects can be increased when Rasagiline is combined with Mianserin. |
| Esmirtazapine | The risk or severity of adverse effects can be increased when Rasagiline is combined with Esmirtazapine. |
| Setiptiline | The risk or severity of adverse effects can be increased when Rasagiline is combined with Setiptiline. |
| Aptazapine | The risk or severity of adverse effects can be increased when Rasagiline is combined with Aptazapine. |
| Mequitazine | Rasagiline may increase the anticholinergic activities of Mequitazine. |
| Methadone | The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Methadone. |